Roquefort Therapeutics plc
ROQ.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £5 | £9 | £7 | £3 |
| - Cash | £0 | £1 | £2 | £1 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £5 | £9 | £5 | £2 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -100% | – | -100% | – |
| Gross Profit | -£0 | £0 | £0 | -£0 |
| % Margin | – | 100% | – | -1,300.4% |
| EBITDA | -£1 | -£2 | £0 | -£0 |
| % Margin | – | -964.2% | – | -49,012.9% |
| Net Income | -£1 | -£2 | -£2 | -£1 |
| % Margin | – | -872.3% | – | -127,598.5% |
| EPS Diluted | -0.008 | -0.014 | -0.016 | -0.037 |
| % Growth | 44.4% | 13.5% | 58% | – |
| Operating Cash Flow | -£1 | -£2 | -£2 | -£3 |
| Capital Expenditures | £0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£1 | -£2 | -£2 | -£3 |